News Channels

17 Mar 2017 Therapeutic antibodies account for two-thirds of total biologics sales in 2016
17 Mar 2017 Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemia
17 Mar 2017 Provecs Medical closes immuno-oncology collaboration with Medac
17 Mar 2017 BELLUS Health Announces the Sale of Subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals
17 Mar 2017 AstraZeneca receives Complete Response Letter from US FDA for ZS-9 (sodium zirconium cyclosilicate) for hyperkalaemia
17 Mar 2017 AstraZeneca and Circassia enter strategic collaboration in respiratory disease
16 Mar 2017 Shire Receives European Approval for Label Extension of CINRYZE®▼(C1 inhibitor ) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE
16 Mar 2017 Helmsley Charitable Trust and Akston Biosciences Corporation Announce Partnership to Advance Novel Technology to Treat Type 1 Diabetes
16 Mar 2017 Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple Sclerosis
16 Mar 2017 Asana BioSciences Announces FDA Acceptance of the IND Application for its Novel SYK-JAK Inhibitor for Evaluation in Atopic Dermatitis
16 Mar 2017 Oncolytics Biotech® Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN® in Combination with Imnovid® or Revlimid® in Patients with Myeloma
16 Mar 2017 Medicenna BioPharma Announces Strategic Collaboration with MD Anderson Cancer Center to Advance Next Generation Empowered Cytokines
15 Mar 2017 GSK announces US regulatory submission seeking expanded indication for Fluarix® Quadrivalent (Influenza Vaccine) for infants 6 months and older
15 Mar 2017 Vtesse Completes Enrollment of Phase 2b/3 Pivotal Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease
15 Mar 2017 BriaCell Receives FDA Clearance to Initiate Phase I/IIa Clinical Trial of BriaVax(TM) in Patients with Advanced Breast Cancer
15 Mar 2017 Catalyst Pharmaceuticals Announces Positive Data from Investigator-Sponsored Trial of Firdapse(R) in treating MuSK Antibody Positive Myasthenia Gravis
15 Mar 2017 Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy
15 Mar 2017 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
15 Mar 2017 Lynparza Phase III SOLO-2 data demonstrate progression-free survival benefit in BRCA-mutated ovarian cancer as maintenance therapy
14 Mar 2017 Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing